Trans-catheter mitral valve implantation (TMVI) is actually the most attractive technique for treating patients with severe mitral regurgitation, who are denied surgical therapy. Recently, trans-catheter implantation of aortic biological prosthesis in mitral position has been done in compassionate cases, and very few experiences of TMVI in native non-calcified valves have been recently reported in very-high-risk patients, mainly with functional mitral regurgitation.
Here, we report our case of TMVI using the second-generation CardiAQ prostheisis (CardiAQ Valve Technologies, Irvine, California, USA), reviewing the current state of the art.
aDepartment of Cardiovascular Disease
bDepartment of Cardiac Surgery, University of Rome ‘Tor Vergata’, Rome, Italy
cDepartment of Cardiac Surgery, St Francis Hospital, Hartford, Connecticut, USA
dDepartment of Anaesthesia, University of Rome ‘Tor Vergata’, Rome, Italy
Correspondence to Gian Paolo Ussia, MD, Department of Cardiovascular Disease, University of Rome ‘Tor Vergata’, Rome, Viale Oxford, 81 00133 Rome, ItalyTel: +39 06 20904009; fax: +39 06 20904008; e-mail: firstname.lastname@example.org
Received 11 June, 2015
Revised 23 September, 2015
Accepted 23 September, 2015